Indazole containing macrocycles and therapeutic uses thereof
Indazole macrocycle compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole macrocycle compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.
1. A compound, or a pharmaceutically acceptable salt thereof, of Formula I:
wherein:
Ring A is a 5-6-membered heteroaryl optionally substituted with 1-4 R 1 ;
L is -L 1 -L 2 -L 3 -L 4 -;
L 1 is selected from the group consisting of unsubstituted —(C 1-3 alkylene)-, —NR 2 —, —NR 3 (C═O)—, —(C═O)NR 3 —, and —O—;
L 2 is selected from the group consisting of unsubstituted —(C 1-6 alkylene)- and —NR 2 —;
L 3 is selected from the group consisting of unsubstituted —(C 1-6 alkylene)-, —O—, and -carbocyclylene- optionally substituted with one or more halides;
L 4 is selected from the group consisting of unsubstituted —(C 1-6 alkylene)-, —O—, —NR 2 —, —NR 3 (C═O)—, —(C═O)NR 3 —, -arylene- optionally substituted with 1-5 R 4 , and -heteroarylene- optionally substituted with 1-4 R 5 ;
with the proviso that —NR 2 — and —O— are not adjacent to each other;
with the proviso that two —O— are not adjacent to each other;
with the proviso that two —NR 3 (C═O)— and/or —(C═O)NR 3 —, are not adjacent to each other;
each R 1 is selected from the group consisting of halide, unsubstituted —(C 1-3 alkyl), unsubstituted —(C 1-3 haloalkyl), and —CN;
each R 2 is selected from the group consisting of H and unsubstituted —(C 1-6 alkyl);
each R 3 is selected from the group consisting of H and unsubstituted —(C 1-6 alkyl);
each R 4 is selected from the group consisting of halide, unsubstituted —(C 1-6 alkyl), unsubstituted —(C 1-6 haloalkyl), and —CN;
each R 5 is selected from the group consisting of halide, unsubstituted —(C 1-6 alkyl), unsubstituted —(C 1-6 haloalkyl), and —CN;
Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , and Y 6 are independently selected from the group consisting of carbon and nitrogen; wherein
if Y is nitrogen then Y 2 and Y 3 are CH;
if Y 2 is nitrogen then Y 1 and Y 3 are CH;
if Y 3 is nitrogen then Y 1 and Y 2 are CH;
if Y 4 is nitrogen then Y 5 and Y 6 are CH;
if Y 5 is nitrogen then Y 4 and Y 6 are CH; and
if Y 6 is nitrogen then Y 4 and Y 5 are CH.
2. The compound of claim 1 , wherein Ring A is pyridinyl.
3. The compound of claim 1 , wherein Ring A is pyrazolyl.
4. The compound of claim 1 , wherein L 1 is selected from the group consisting of —(CH 2 )—, —NH—, —NH(C═O)—, and —O—.
5. The compound of claim 4 , wherein L 2 is selected from the group consisting of —(CH 2 )—, —(CH 2 CH 2 )—, —(CH 2 CH 2 CH 2 )—, —NH—, and —NMe-.
6. The compound of claim 5 , wherein L 3 is selected from the group consisting of —(CH 2 CH 2 )—, —(CH 2 CH 2 CH 2 )—, —(CH 2 CH 2 CH 2 CH 2 )—, —O—, and -cyclohexylene-.
7. The compound of claim 6 , wherein L 4 is selected from the group consisting of —NMe-, —NH(C═O)—, -phenylene-, and -triazolylene-.
8. The compound of claim 7 , wherein L is 5-9 atoms in length.
9. The compound of claim 8 , wherein L is 7-8 atoms in length.
10. The compound of claim 1 , wherein Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , and Y 6 are all carbon.
11. The compound of claim 1 , wherein Y 2 is N and Y 1 , Y 3 , Y 4 , Y 5 , and Y 6 are all carbon.
12. The compound of claim 1 , wherein Y 5 is N and Y 1 , Y 2 , Y 3 , Y 4 , and Y 6 are all carbon.
13. The compound of claim 1 , wherein Y 2 and Y 5 are N and Y 1 , Y 3 , Y 4 , and Y 6 are all carbon.
14. The compound of claim 1 , wherein the compound of Formula I is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.
15. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
16. A method of treating a disorder or disease in a patient, wherein the disorder or disease is selected from the group consisting of: cancer, pulmonary fibrosis, idiopathic pulmonary fibrosis (IPF), degenerative disc disease, bone/osteoporotic fractures, a bone or cartilage disease, osteoarthritis, lung disease, a fibrotic disorder, the method comprising administering to the patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt, or a pharmaceutical composition.